Skip to Content

News Releases

Feb 02 2022
SomaLogic to Participate in Upcoming Investor Conferences
BOULDER, Colo., Feb. 02, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the following virtual investor conferences. BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Feb 02 2022
SomaLogic to provide 105 million protein measurements from 15,000 samples as part of the Multi-Ethnic Study of Atherosclerosis (MESA) Study
Data will be available to researchers studying a wide range of disease states BOULDER, Colo., Feb. 02, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that the company will begin assaying samples from the Multi-Ethnic Study of
Jan 11 2022
SomaLogic Announces Preliminary Revenue for Full Year 2021 Above Guidance Range
Presenting at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 8:15 a.m. Eastern Time BOULDER, Colo., Jan. 11, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced preliminary, unaudited revenue expectations
Jan 10 2022
SomaLogic Announces Appointment of Adam Taich as Chief Business Officer
BOULDER, Colo., Jan. 10, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that Adam Taich has joined the company as the Chief Business Officer. In this newly created role, Adam will have broad responsibility across SomaLogic’s rapidly
Jan 07 2022
SomaLogic Announces Analyst and Investor Meeting on February 4, 2022
BOULDER, Colo., Jan. 07, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, will host a virtual Analyst and Investor Meeting on Friday, February 4, 2022, beginning at 10:00 a.m. Eastern Time. The virtual event will feature presentations from company leaders
Jan 05 2022
SomaLogic announces exclusive partnership with Illumina to develop sequencing-based proteomic solutions
Co-developed and co-branded products to combine market-leading proteomic and genomic analysis platforms BOULDER, Colo., Jan. 05, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced a worldwide strategic collaboration with Illumina, a
Displaying 11 - 16 of 16